Drug intelligence / Profile preview

P1A

Development stage: Unknown
Lead developer: Theriva Biologics

Overview

P1A is a compound referenced as a drug candidate developed by Synthetic Biologics, Inc. There is no publicly available evidence for a standardized generic name, approval, or late-stage clinical development. No information is available regarding its mechanism of action, modality, molecular structure, pharmacology, or indication. No details on clinical trials or definitive therapeutic target exist in accessible sources, and no regulatory or nonproprietary naming information is associated with this code name.

Beyond the preview

Go deeper on P1A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P1A.

Explore the full profile